The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy

The prognosis for people with the high-grade brain tumor glioblastoma is very poor, due largely to low cell death in response to genotoxic therapy. The transcription factor BCL6, a protein that normally suppresses the DNA damage response during immune cell maturation, and a known driver of B-cell ly...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:PLoS One
Main Authors: Fabre, Marie-Sophie, Stanton, Nicole M., Slatter, Tania L., Lee, Samuel, Senanayake, Dinindu, Gordon, Rosemary M. A., Castro, M. Leticia, Rowe, Matthew R., Taha, Ahmad, Royds, Janice A., Hung, Noelyn, Melnick, Ari M., McConnell, Melanie J.
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2020
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7176076/
https://ncbi.nlm.nih.gov/pubmed/32320427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0231470
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים